drugset / Trial / NCT00119249

Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

NCT00119249 ↗

Phase 2 Completed 74 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. This phase II trial is studying how well sorafenib works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery

Timeline

Start
2005-06
Primary completion
2007-11
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Sorafenib Small molecule 400 mg Oral

Indications